Dec 5, 2024 6:45 am EST BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
Nov 13, 2024 7:00 am EST BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
Nov 12, 2024 4:05 pm EST BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 6, 2024 7:00 am EST BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium
Nov 5, 2024 7:10 am EST BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
Oct 31, 2024 7:00 am EDT BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
Oct 10, 2024 7:00 am EDT BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events
Oct 3, 2024 4:15 pm EDT BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Sep 19, 2024 6:55 am EDT BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs